Dimerix (#ASX: $DXB)'s DMX-200 has been selected for inclusion in the protocol as a new treatment arm in the global REMAP-CAP program aimed at treating patients with ARDS as a result of #COVID-19. Opened high at over 85% gain. https://t.co/1n6te1BoVj. #stocks #biotech #clinical. https://t.co/U2JEpkryGY